AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
30 Winter Street
Boston
Massachusetts
02108
United States
457 articles about AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
-
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
1/20/2022
AVEO Oncology announced that new efficacy and safety data from the first line of the phase 1b/2 DEDUCTIVE study of FOTIVDA® in combination with IMFINZI® in previously untreated metastatic hepatocellular carcinoma are being presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
AVEO Oncology Highlights Recent Progress and 2022 Outlook
1/4/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
1/4/2022
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX ® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO’s investigational potent
-
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
12/22/2021
AVEO Oncology today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th.
-
BioSpace Movers & Shakers, Dec. 3
12/3/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
12/1/2021
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer.
-
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences - Nov 10, 2021
11/10/2021
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, announced that members of its senior management team will participate in two upcoming virtual investor conferences.
-
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
11/8/2021
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the third quarter ended September 30, 2021 and provided a business update.
-
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
11/1/2021
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
-
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
9/20/2021
AVEO Oncology today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC).
-
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
8/30/2021
AVEO Oncology announced that members of its senior management team will participate in two upcoming virtual investor conferences.
-
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
8/5/2021
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the second quarter ended June 30, 2021, and provided a business update.
-
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
7/29/2021
AVEO Oncology, a commercial and clinical development stage biopharmaceutical company, announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021.
-
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
7/8/2021
AVEO Oncology announced that it will host a key opinion leader webinar focusing on FOTIVDA®, AVEO’s oral, once-daily, differentiated vascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of adult patients with relapsed or refractory renal cell carcinoma following two or more prior systemic therapies, on Friday, July 16, 2021 at 12:00 p.m. Eastern Time.
-
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
6/7/2021
AVEO Oncology, a commercial and clinical development stage biopharmaceutical company, announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor, being studied in head and neck squamous cell carcinoma on Wednesday, June 16, 2021 at 2:00 p.m. Eastern Time.
-
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
5/25/2021
AVEO Oncology announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time.
-
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
5/19/2021
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA ® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma - Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up -
-
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
5/19/2021
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC – Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX ® ) Combination – – 38% ORR, Including 13% CRs and 25% PRs, and Median PFS of 4.1 months Observed in HPV Negative Patients Treated with Ficlatuzumab/Cetuximab Combination –
-
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
5/10/2021
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.